Literature DB >> 7822338

Structure-function relationships in human interleukin-11. Identification of regions involved in activity by chemical modification and site-directed mutagenesis.

M J Czupryn1, J M McCoy, H A Scoble.   

Abstract

Chemical modification approaches combined with site-directed and deletion mutagenesis have been used to identify functionally critical regions/residues of recombinant human IL-11 (rhIL-11). Incubation of rhIL-11 with iodoacetic acid results in specific alkylation of a single methionine residue, Met58, and a 25-fold reduction of in vitro biological activity on mouse plasmacytoma cells. A similar decrease in activity is observed when Met58 is substituted with Ala, Leu, Gln, Glu, or Lys by site-directed mutagenesis. Treatment of rhIL-11 with succinic anhydride leads to modification of the amino-terminal amino group and partial labeling of 2 lysines, Lys41 and Lys98, and to a 3-fold decrease in activity. The activity losses can be attributed to modification of the lysine residues, since the succinyl derivative of the amino terminus is fully active. In addition, carboxyl-terminal deletion mutagenesis studies have demonstrated that removal of the last 4 residues reduces rhIL-11 activity 25-fold, whereas removal of 8 or more amino acids results in an inactive molecule. Based on secondary structure predictions and the location of exon/intron boundaries in the IL-11 genomic structure, we propose a four-helix bundle topology as a structural model for rhIL-11. This model has been tested by limited proteolysis using three side chain-specific endoproteinases. A limited number of protease-sensitive cleavage sites are present in rhIL-11, and all but two are located in the postulated helix interconnecting loops or at helix termini. alpha-Helices, which in the proposed structure form a compact core of the molecule, are inaccessible to digestion under limiting conditions. According to the model, Met58, Lys41 and Lys98 are located on the surface of the molecule, in agreement with their preferential accessibility to chemical modifications. By analogy with human growth hormone, we postulate that Met58 and the carboxyl terminus of rhIL-11 are involved in the primary receptor binding site (site I), whereas Lys41 and Lys98 may be a part of binding site II.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822338     DOI: 10.1074/jbc.270.2.978

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Activating mechanism of CNTF and related cytokines.

Authors:  M Inoue; C Nakayama; H Noguchi
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

2.  Multiple and highly divergent IL-11 genes in teleost fish.

Authors:  Mark O Huising; Corine P Kruiswijk; Jessica E van Schijndel; Huub F J Savelkoul; Gert Flik; B M Lidy Verburg-van Kemenade
Journal:  Immunogenetics       Date:  2005-07-08       Impact factor: 2.846

Review 3.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

4.  Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants.

Authors:  Saeko Yanaka; 中冴子 谷; Emiko Sano; 野恵海子 佐; Norio Naruse; 瀬紀男 成; Kin-Ichiro Miura; 浦謹一郎 三; Mutsumi Futatsumori-Sugai; ツ森ー菅井睦美 二; Jose M M Caaveiro; Kouhei Tsumoto; 本浩平 津
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

5.  Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11.

Authors:  Wei Zhang; J Marta J Czupryn; Philip T Boyle; John Amari
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

6.  Characterization of a potent human interleukin-11 agonist.

Authors:  Dimitri Harmegnies; Xiao-Ming Wang; Paul Vandenbussche; Arnaud Leon; Patricia Vusio; Joachim Grötzinger; Yannick Jacques; Erik Goormaghtigh; Bart Devreese; Jean Content
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

7.  A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Authors:  Marina Cardó-Vila; Amado J Zurita; Ricardo J Giordano; Jessica Sun; Roberto Rangel; Liliana Guzman-Rojas; Cristiane D Anobom; Ana P Valente; Fábio C L Almeida; Johanna Lahdenranta; Mikhail G Kolonin; Wadih Arap; Renata Pasqualini
Journal:  PLoS One       Date:  2008-10-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.